Market Place
Sourcing Support
ImmunoForge`s IND Approval For Pemziviptadil Ph 2 Trial & KF1601 Ph 1
14 Jan 2025 //
PR NEWSWIRE
ImmunoForge Doses First Patient in Phase 2 Clinical Trial of Froniglutide
17 Oct 2023 //
PR NEWSWIRE
ImmunoForge Expands Drug Development Licensing Agreement with Duke University
18 May 2023 //
PR NEWSWIRE
Immunoforge Inc. receives U.S. FDA ODD for Treatment of Polymyositis
27 Sep 2021 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.